Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136688> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4324136688 endingPage "TPS434" @default.
- W4324136688 startingPage "TPS434" @default.
- W4324136688 abstract "TPS434 Background: At diagnosis, 10 to 15% of testicular pure seminomas have a stage II defined by the presence of retroperitoneal lymph node metastases. The optimal choice of treatment modalities are associated with excellent efficacy but also acute and late toxicities. De-escalating treatment for seminoma patients with stage IIb, IIc and III and good prognosis according to IGCCCG (International Germ Cell Cancer Collaborative Group) based on negative FDG-PET (Fluorodeoxyglucose Positron Emission Tomography) after 2 cycles of EP (etoposide, cisplatine) chemotherapy seems feasible and safe according to SEMITEP cohort 2 results (Loriot Y, and al GETUG SEMITEP Trial: Eur Urol. 2022 Aug;82(2):172-179). Serum levels of microRNA (miR)-371a-3p (miRNA-M371) have been significantly associated with clinical stage and response to treatment in testicular germ cell tumors, with sensitivity and specificity higher than those of classic markers. The aim of the study NCT05529251 is to propose a new therapeutic approach for the stages IIa/IIb. Methods: This phase II, multicenter, prospective, randomized, non-comparative, de-escalation study will include patient with primary testicular seminomatous germ cell tumor with stage IIa/IIb < 3 cm in largest diameter seminoma, histologically proved after orchiectomy and good prognosis according to IGCCCG and LDH (Lactate DesHydogenase) < 2.5 x Upper Limit of Normal (ULN). They must have progressive disease and no prior treatment with radiotherapy or chemotherapy. In case of negative week-3 (after 1 EP cycle) PET-scan, patients will be randomized according to 2 arms ARM A: Boost of radiotherapy 20 to 30 Gray (Gy); ARM B Carboplatin AUC7 chemotherapy. In case of positive week-3 PET-scan: 3 courses of EP chemotherapy (ARM C). Primary outcome will include progression-free rate at 36 months. Secondary Outcome Measures will be serum level of miRNA M371, correlation with response to treatments and PET scan results, overall survival (OS), quality of life and tolerance to treatment. Blood samples (miRNA-M371) will be collected at screening, at the time of randomization before second cycle of chemotherapy or radiotherapy, at the end of treatment and at relapse. Enrollment has started in October 2022. A total of 90 patients will be included in the interventional study, leading to approximately 60 patients with negative FDG-PET randomized. Clinical trial information: NCT05529251 ." @default.
- W4324136688 created "2023-03-15" @default.
- W4324136688 creator A5001456598 @default.
- W4324136688 creator A5011183093 @default.
- W4324136688 creator A5029182920 @default.
- W4324136688 creator A5044502328 @default.
- W4324136688 creator A5044945353 @default.
- W4324136688 creator A5072873173 @default.
- W4324136688 date "2023-02-20" @default.
- W4324136688 modified "2023-09-30" @default.
- W4324136688 title "EDEN (Etude Désescalade sEmiNome): Prospective therapeutic de-escalation and miRNA-M371 biomarker evaluation phase II study for stage IIa/IIb < 3 cm seminomas." @default.
- W4324136688 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.tps434" @default.
- W4324136688 hasPublicationYear "2023" @default.
- W4324136688 type Work @default.
- W4324136688 citedByCount "0" @default.
- W4324136688 crossrefType "journal-article" @default.
- W4324136688 hasAuthorship W4324136688A5001456598 @default.
- W4324136688 hasAuthorship W4324136688A5011183093 @default.
- W4324136688 hasAuthorship W4324136688A5029182920 @default.
- W4324136688 hasAuthorship W4324136688A5044502328 @default.
- W4324136688 hasAuthorship W4324136688A5044945353 @default.
- W4324136688 hasAuthorship W4324136688A5072873173 @default.
- W4324136688 hasConcept C126322002 @default.
- W4324136688 hasConcept C143998085 @default.
- W4324136688 hasConcept C146357865 @default.
- W4324136688 hasConcept C151730666 @default.
- W4324136688 hasConcept C188816634 @default.
- W4324136688 hasConcept C2775842073 @default.
- W4324136688 hasConcept C2776212926 @default.
- W4324136688 hasConcept C2776694085 @default.
- W4324136688 hasConcept C2776938808 @default.
- W4324136688 hasConcept C2777415128 @default.
- W4324136688 hasConcept C2778074268 @default.
- W4324136688 hasConcept C2778119113 @default.
- W4324136688 hasConcept C2780258809 @default.
- W4324136688 hasConcept C2780849966 @default.
- W4324136688 hasConcept C2989005 @default.
- W4324136688 hasConcept C31760486 @default.
- W4324136688 hasConcept C509974204 @default.
- W4324136688 hasConcept C71924100 @default.
- W4324136688 hasConcept C86803240 @default.
- W4324136688 hasConceptScore W4324136688C126322002 @default.
- W4324136688 hasConceptScore W4324136688C143998085 @default.
- W4324136688 hasConceptScore W4324136688C146357865 @default.
- W4324136688 hasConceptScore W4324136688C151730666 @default.
- W4324136688 hasConceptScore W4324136688C188816634 @default.
- W4324136688 hasConceptScore W4324136688C2775842073 @default.
- W4324136688 hasConceptScore W4324136688C2776212926 @default.
- W4324136688 hasConceptScore W4324136688C2776694085 @default.
- W4324136688 hasConceptScore W4324136688C2776938808 @default.
- W4324136688 hasConceptScore W4324136688C2777415128 @default.
- W4324136688 hasConceptScore W4324136688C2778074268 @default.
- W4324136688 hasConceptScore W4324136688C2778119113 @default.
- W4324136688 hasConceptScore W4324136688C2780258809 @default.
- W4324136688 hasConceptScore W4324136688C2780849966 @default.
- W4324136688 hasConceptScore W4324136688C2989005 @default.
- W4324136688 hasConceptScore W4324136688C31760486 @default.
- W4324136688 hasConceptScore W4324136688C509974204 @default.
- W4324136688 hasConceptScore W4324136688C71924100 @default.
- W4324136688 hasConceptScore W4324136688C86803240 @default.
- W4324136688 hasIssue "6_suppl" @default.
- W4324136688 hasLocation W43241366881 @default.
- W4324136688 hasOpenAccess W4324136688 @default.
- W4324136688 hasPrimaryLocation W43241366881 @default.
- W4324136688 hasRelatedWork W2078125348 @default.
- W4324136688 hasRelatedWork W2085545986 @default.
- W4324136688 hasRelatedWork W2086852418 @default.
- W4324136688 hasRelatedWork W2145575862 @default.
- W4324136688 hasRelatedWork W2269400351 @default.
- W4324136688 hasRelatedWork W2383214251 @default.
- W4324136688 hasRelatedWork W2468136680 @default.
- W4324136688 hasRelatedWork W3030381566 @default.
- W4324136688 hasRelatedWork W3130060490 @default.
- W4324136688 hasRelatedWork W4324136688 @default.
- W4324136688 hasVolume "41" @default.
- W4324136688 isParatext "false" @default.
- W4324136688 isRetracted "false" @default.
- W4324136688 workType "article" @default.